Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
AssigneeCara Therapeutics, Inc.
InventorsDerek T. CHALMERS, James B. JONES
Life of this patent
Estimating the term…
Loading patent…
AssigneeCara Therapeutics, Inc.
InventorsDerek T. CHALMERS, James B. JONES
Estimating the term…
A method for preventing, inhibiting or treating nausea and/or vomiting in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the subject. The nausea and/or vomiting can be associated with use of an opioid, such as morphine or fentanyl. The peripherally-restricted kappa opioid receptor agonist can be an L-amino acid-containing peptide, a D-amino acid-containing peptide, or a synthetic peptide amide, such as for instance, D-Phe-D-Phe-D-Leu-D-Lys-[ω(4-aminopiperidine-4-carboxylic acid)]-OH (CR845).
A method for preventing, inhibiting or treating nausea and/or vomiting in a mammalian subject, the method comprising administering an effective amount of a peripherally-restricted kappa opioid receptor agonist to the mammalian subject.
Dependencies are inferred from the claim text.